CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new monoclonal antibody-based therapies targeting the IL-7/IL-7 receptor signaling pathway to treat acute lymphoblastic leukemia and other malignancies. The goal is to improve treatment outcomes while minimizing side effects associated with traditional chemotherapy.
Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults.
The use of risk-adjusted multi-agent intensive chemotherapy has led to a remarkable improvement in treatment outcome of pediatric cases, with more than 80% of children with ALL being alive and disease-free at 5 years.
However, a significant number of relapses still occur, whose prognosis is dismal, and the intensive regimens…
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
